Top Markets
#1 Helium Helium +109.41%
#2 MowCat MowCat +103.90%
#3 Seeker Seeker +74.55%
#4 Pons Pons +47.43%
#5 AI XOVIA AI XOVIA +39.39%
#6 UnifAI Network UnifAI Network +33.34%
#7 Bounce Bounce +30.38%
#8 Tensor Tensor +22.88%
#9 Zylo Ecosystem Zylo Ecosystem +21.26%
#10 pipedog pipedog +20.42%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classificação em ações #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Preço da ação
$8.74
Última sincronização: 2026-08-28
Valor de mercado
$699.74M
Variação (1 dia)
-4.85%
Variação (1 ano)
-2.29%
País
US
Negociar BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

Healthcare
Receita da BridgeBio Oncology Therapeutics Inc. (BBOT)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da BridgeBio Oncology Therapeutics Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da BridgeBio Oncology Therapeutics Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH